Skip to main content
  • Careers
  • Contact
  • en   it

Navigazione principale

  • About us
  • GMP Solutions
    • Our services
    • Viral Vector
    • Genetically Modified Cells
    • Facilities
  • PIPELINE
    • Our products
    • CAR-T platform
    • CAR-NK
  • Investors
  • Governance
  • News & Events

Navigazione principale

  • About us
  • GMP Solutions
    • Our services
    • Viral Vector
    • Genetically Modified Cells
    • Facilities
  • PIPELINE
    • Our products
    • CAR-T platform
    • CAR-NK
  • Investors
  • Governance
  • News & Events

MolMed is now part of AGC Biologics

Learn more

AGC Biologics

Pipeline

MolMed is a clinical biotech company focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and immuno-oncology

Zalmoxis®

Patient-specific cell therapy based on the use of the TK suicide gene, allowing the transplantation of hematopoietic stem cells from partially matched donors, in the absence of immunosuppression

CAR-T

CAR-T CD44v6: Immune gene-therapy autologus product, consisting of T lymphocytes genetically modified to express the CAR, which allows selective recognition and elimination of tumor cells expressing the CD44v6 antigen
Other CAR-T: CAR-T cells that target other tumor antigens. The targets have been chosen with a multidisciplinary approach in order to be potentially effective against both hematological malignancies and solid tumors

CAR-NK

Innovative CAR platform based on Natural Killer cells to develop "off-the-shelf" products, able to treat many patients with a single manufactured batch

NGR-hTNF

Recombinant protein that allows to increase the concentration of immunity cells and chemotherapeutic drugs at the tumor level through the permeabilization of tumor vessels

Proprietary Pipeline

Subscribe to press releases

By subscribing to this newsletter, you confirm that you have read the Privacy Policy and agree to receive MolMed's press releases

Contact Us

Luca Alberici, CBO

business.development@molmed.com

Download

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations. 
In addition, the "work with us" section is still active, while the contact details are no longer accessible.

Leading the way in Cell and Gene therapy

MolMed S.p.A.
Via Olgettina, 58
20132 Milano, Italy
+39 0221277.1
info@molmed.com
Privacy & Cookie Policy

About us

About us ▾

aboutus

  • Business model
  • Our Team
  • Scientific advisory board
  • Hystory
  • Careers

Pipeline

Pipeline ▾

pipeline

  • Our products
  • CAR-T platform
  • CAR-NK

GMP Solutions

GMP Solutions ▾

GMP Solutions footer ENG

  • Our services
  • Viral Vectors
  • Genetically Modified Cells
  • Facilities

Investors

Investors ▾

Investors

  • Stock informations
  • Presentations
  • Notices
  • Events
  • Financial Calendar

Governance

Governance ▾

Governance

  • Corporate governance model
  • Corporate governance rules
  • Business ethics
  • Corporate governance reports

News & Events

News ▾

News

  • News & Events
MolMed S.p.A. Via Olgettina, 58 - 20132 Milano, Italia | Tel. +39 0221277.1 - Fax +39 02 21277.325 | info@molmed.com - www.molmed.com
Capitale Sociale € 21.819.020,83 i.v. - REA n.1506630 - N. iscrizione Reg. Imprese di Milano - C. F. e P. IVA 11887610159